Adicet Bio Appoints Dr. Blake Aftab as Vice President of Research
April 13 2021 - 7:00AM
Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company
discovering and developing allogeneic gamma delta T cell therapies
for cancer and other diseases, today announced the appointment of
Blake Aftab, Ph.D., as Vice President of Research. Dr. Aftab will
lead Adicet’s research group and will further develop existing and
new opportunities for the Company’s gamma delta T cell platform.
“We are very excited to have Blake join Adicet, and lead our
research team as we advance the clinical development of ADI-001 and
rapidly develop a deep pipeline of “off-the-shelf” gamma delta T
cell therapies,” said Stewart Abbot, Chief Scientific and Operating
Officer of Adicet. “Blake has committed his career, with notable
success, to researching and developing cell therapies across a
variety of indications including oncology, infectious disease, and
autoimmune conditions, while also building strong associations with
academic and industry leaders. His expertise in the allogeneic T
cell therapy landscape will further enable Adicet to advance its
product candidates into the clinic and expand its pipeline of
‘off-the-shelf’ gamma delta T cell product candidates.”
“I’m delighted to join Adicet at this exciting time for the
company, with ADI-001 progressing into clinical development,” said
Dr. Aftab. “I believe the Company’s novel targeting approach and
'off-the-shelf' gamma delta T cell platform positions Adicet to
provide potentially transformative treatment options for patients.
I look forward to working with the team to translate the promise of
Adicet’s science and technology platform toward medicines that
improve the lives of patients suffering from solid and hematologic
malignancies.”
Dr. Aftab has nearly 20 years of rich experience in academia,
biotech and pharmaceutical industries developing multiple
therapeutic modalities including small molecules, biologics,
antibody-drug conjugates and cell therapies through all stages drug
development. He joins Adicet from Atara Biotherapeutics, Inc., a
publicly traded immunotherapy company, where, as Vice President and
Head of Preclinical Science and Translational Medicine, he
contributed to the company’s initial transition to cell therapy and
led the focus on developing Allo-CAR T cell capabilities.
Previously, Dr. Aftab led multiple research programs at University
of California, San Francisco focused on drug discovery and clinical
translation in multiple myeloma, including
early research supporting targeted approaches for CD38
and other impactful targets of interest for CAR-T therapies. Dr.
Aftab received his Ph.D. from The Johns Hopkins University School
of Medicine and holds a B.Sc. in Pharmacology and Drug Discovery,
from The University of California, Santa Barbara.
About Adicet Bio, Inc.
Adicet Bio, Inc. is a biotechnology company discovering and
developing allogeneic gamma delta T cell therapies for cancer and
other diseases. Adicet is advancing a pipeline of "off-the-shelf"
gamma delta T cells, engineered with chimeric antigen receptors and
T cell receptor-like antibodies to enhance selective tumor
targeting, facilitate innate and adaptive anti-tumor immune
response, and improve persistence for durable activity in patients.
For more information, please visit our website at
http://www.adicetbio.com.
Forward-Looking Statements
This press release contains "forward-looking statements" of
Adicet within the meaning of the Private Securities Litigation
Reform Act of 1995 relating to business and operations of Adicet
including, but not limited to Adicet's advancement of ADI-001 for
the treatment of B cell non-Hodgkin's lymphoma, including future
plans or expectations as well as the expected potential therapeutic
effects, Adicet’s growth as a company and the anticipated
contribution of its executives to Adicet’s operations and progress,
and expectations regarding its other CAR gamma delta T cell therapy
development activities.
Any forward-looking statements in this press release are based
on management's current expectations and beliefs of future events,
and are subject to a number of risks and uncertainties that could
cause actual results to differ materially and adversely from those
set forth in or implied by such forward-looking statements,
including without limitation, the effect of COVID-19 on our
business and financial results, including with respect to
disruptions to our clinical trials, business operations, and
ability to raise additional capital; Adicet's ability to execute on
its strategy; that positive results from a clinical study may not
necessarily be predictive of the results of future or ongoing
clinical studies; Adicet’s ability to discover and develop
additional product candidates; future clinical studies may fail to
demonstrate adequate safety and efficacy of our product candidates,
which would prevent, delay, or limit the scope of regulatory
approval and commercialization; regulatory approval processes of
the FDA and comparable foreign regulatory authorities are lengthy,
time–consuming, and inherently unpredictable; regulatory
developments in the United States and foreign countries; and the
company's estimates regarding expenses, future revenue, and capital
requirements. For a discussion of these and other risks and
uncertainties, and other important factors, any of which could
cause Adicet's actual results to differ from those contained in the
forward-looking statements, see the section entitled "Risk Factors"
in Adicet's most recent annual report on Form 10-K and our periodic
reports on Form 10-Q and Form 8-K filed with the SEC, as well as
discussions of potential risks, uncertainties, and other important
factors in Adicet's other filings with the SEC. All information in
this press release is as of the date of the release, and Adicet
undertakes no duty to update this information unless required by
law.
Adicet Bio., Inc.Investor and Media
ContactsAnne Bowdidgeabowdidge@adicetbio.com
Janhavi MohiteStern Investor Relations,
Inc.212-362-1200janhavi.mohite@sternir.com
Adicet Bio (NASDAQ:ACET)
Historical Stock Chart
From Jun 2024 to Jul 2024
Adicet Bio (NASDAQ:ACET)
Historical Stock Chart
From Jul 2023 to Jul 2024